Published in Proc Natl Acad Sci U S A on December 15, 1992
Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci U S A (1994) 1.22
Milk composition and lactation of beta-casein-deficient mice. Proc Natl Acad Sci U S A (1994) 1.03
Pigs taking wing with transposons and recombinases. Genome Biol (2007) 0.94
Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. Proc Natl Acad Sci U S A (1995) 0.88
Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases. Hum Genet (2016) 0.88
N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Proteomics (2009) 0.86
Production of active bovine tracheal antimicrobial peptide in milk of transgenic mice. Proc Natl Acad Sci U S A (1996) 0.84
Fixing human factor IX (fIX): correction of a cryptic RNA splice enables the production of biologically active fIX in the mammary gland of transgenic mice. Proc Natl Acad Sci U S A (1995) 0.81
Uromodulin promoter directs high-level expression of biologically active human alpha1-antitrypsin into mouse urine. Biochem J (2002) 0.80
Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the mammary gland by using replication-defective retrovirus vectors. Proc Natl Acad Sci U S A (1994) 0.77
Secretion of human protein C in mouse milk. Int J Mol Sci (2015) 0.76
The mammary gland: protein factory of the future. Environ Health Perspect (1994) 0.76
Expression of human growth hormone in the milk of transgenic rabbits with transgene mapped to the telomere region of chromosome 7q. J Appl Genet (2012) 0.75
Expression of Active Fluorophore Proteins in the Milk of Transgenic Pigs Bypassing the Secretory Pathway. Sci Rep (2016) 0.75
Transgenic approaches for modifying the mammary gland to produce therapeutic proteins. Environ Health Perspect (1994) 0.75
Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A (1989) 7.79
Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci U S A (1985) 7.32
An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Biotechniques (1990) 4.32
The regulation of natural anticoagulant pathways. Science (1987) 2.58
The interaction of a Ca2+-dependent monoclonal antibody with the protein C activation peptide region. Evidence for obligatory Ca2+ binding to both antigen and antibody. J Biol Chem (1988) 2.06
Comparison of the whey acidic protein genes of the rat and mouse. Nucleic Acids Res (1984) 1.81
A milk protein gene promoter directs the expression of human tissue plasminogen activator cDNA to the mammary gland in transgenic mice. Proc Natl Acad Sci U S A (1988) 1.49
High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y) (1991) 1.32
Transgenic production of a variant of human tissue-type plasminogen activator in goat milk: generation of transgenic goats and analysis of expression. Biotechnology (N Y) (1991) 1.27
High-level synthesis of a heterologous milk protein in the mammary glands of transgenic swine. Proc Natl Acad Sci U S A (1991) 1.02
Development of porcine ova that were centrifuged to permit visualization of pronuclei and nuclei. Biol Reprod (1985) 1.00
A gamma-carboxyglutamic acid (gamma) variant (gamma 6D, gamma 7D) of human activated protein C displays greatly reduced activity as an anticoagulant. Biochemistry (1990) 0.93
Production of the mouse whey acidic protein in transgenic pigs during lactation. J Anim Sci (1991) 0.87
Production of biologically active human protein C in the milk of transgenic mice. Ann N Y Acad Sci (1992) 0.87
Protein C: comparison of different assays in normal and abnormal plasma samples. Thromb Res (1987) 0.83
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med (1997) 8.43
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med (1999) 7.81
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization. Science (1986) 4.17
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Differential characteristics of catalase-positive campylobacters correlated with DNA homology groups. Can J Microbiol (1984) 3.93
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Deoxyribonucleic acid homology in bacterial taxonomy: effect of incubation temperature on reaction specificity. J Bacteriol (1968) 3.74
Cloned pigs produced by nuclear transfer from adult somatic cells. Nature (2000) 3.51
Cell wall composition and deoxyribonucleic acid similarities among the anaerobic coryneforms, classical propionibacteria, and strains of Arachnia propionica. J Bacteriol (1972) 3.43
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. Proc Natl Acad Sci U S A (1986) 3.21
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med (1988) 2.84
The pterin molybdenum cofactors. J Biol Chem (1992) 2.74
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion (2000) 2.52
Characterization of the molybdenum cofactor of sulfite oxidase, xanthine, oxidase, and nitrate reductase. Identification of a pteridine as a structural component. J Biol Chem (1980) 2.51
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Tuberculosis: who should prescribe? Br Med J (Clin Res Ed) (1982) 2.41
Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest (1998) 2.37
Nucleic acid homologies among oxidase-negative Moraxella species. J Bacteriol (1970) 2.35
MR urography: technique and application. Radiology (1995) 2.34
Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS (2000) 2.32
Bidirectional effects of cytokines on the growth of Mycobacterium avium within human monocytes. J Immunol (1991) 2.29
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics (2001) 2.29
Structural and metabolic relationship between the molybdenum cofactor and urothione. Proc Natl Acad Sci U S A (1982) 2.26
Taxonomy of the Clostridia: ribosomal ribonucleic acid homologies among the species. J Gen Microbiol (1975) 2.25
Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J (1979) 2.23
Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents (2004) 2.21
Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol (2000) 2.20
Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene (2001) 2.17
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells. Proc Natl Acad Sci U S A (2001) 2.16
Serpulina pilosicoli sp. nov., the agent of porcine intestinal spirochetosis. Int J Syst Bacteriol (1996) 2.14
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis (1999) 2.06
Paradoxical reactions in HIV and pulmonary TB. Chest (1998) 2.05
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
The pterin component of the molybdenum cofactor. Structural characterization of two fluorescent derivatives. J Biol Chem (1984) 1.99
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Distribution of deoxyribonucleic acid complementary to the ribonucleic acid of avian myeloblastosis virus in tissues of normal and tumor-bearing chickens. J Virol (1972) 1.96
Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.94
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
DNA homology studies of the catalase-negative campylobacters and "Campylobacter fecalis," an emended description of Campylobacter sputorum, and proposal of the neotype strain of Campylobacter sputorum. Can J Microbiol (1985) 1.90
The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog (1995) 1.89
Corynebacterium parvum: a synonym for Propionibacterium acnes? J Gen Microbiol (1974) 1.89
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Transient impairment of renal function after streptokinase therapy. Lancet (1989) 1.83
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion (1998) 1.78
Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem (1997) 1.77
Galactosamine glycan of Chondrococcus columnaris. Science (1966) 1.77
The abdominal compartment syndrome is a morbid complication of postinjury damage control surgery. Am J Surg (2001) 1.76
Phthalate esters as environmental contaminants. Nature (1972) 1.76
The effect of bacille Calmette-Guérin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis (1999) 1.76
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.74
Structural features of multiple nifH-like sequences and very biased codon usage in nitrogenase genes of Clostridium pasteurianum. J Bacteriol (1986) 1.72
Mycobacterium africanum subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda. J Clin Microbiol (2002) 1.72
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med (1999) 1.67
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Biventricular pacing decreases the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am J Cardiol (2001) 1.66
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Molecular basis of the biological function of molybdenum. Effect of tungsten on xanthine oxidase and sulfite oxidase in the rat. J Biol Chem (1974) 1.65
Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. J Virol (1997) 1.64
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol (2001) 1.63
Comparative study of six random oral spirochete isolates. Serological heterogeneity of Treponema denticola. J Periodontal Res (1985) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Acetone, Isopropanol, and Butanol Production by Clostridium beijerinckii (syn. Clostridium butylicum) and Clostridium aurantibutyricum. Appl Environ Microbiol (1983) 1.62